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ABSTRACT 
Objective: The aim of our study was to determine whether there is a link between aspects of the 
metabolic syndrome (MetS) and overactive bladder (OAB) in women with lower urinary tract 
symptoms (LUTS).  
Study design: A single-centre prospective study. We evaluated a cohort of consecutive women with 
LUTS attending a tertiary referral urodynamic clinic from October 2012 to January 2015. Obesity, 
diabetes, hypertension and dyslipidaemia were used as markers of MetS. OAB and detrusor 
overactivity (DO) were defined according to the International Urogynaecological 
Association/International Continence Society terminology.  
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Results: Eight hundred and forty women were enrolled. Three hundred and eight (36.6%) had normal 
weight, 260 (31%) were overweight and 272 (32.4%) obese. We identified 168 women (20%) with 
hypertension, 64 (7.6%) with diabetes mellitus, and 98 (11.7%) with dyslipidaemia. Seven hundred 
and four (83.8%) women were diagnosed symptomatically with OAB and 305 (36.3%) were diagnosed 
urodynamically with DO. Obesity (p<0.001) was the only independent predictor for OAB (OR 1.09, 95% 
CI 1.05-1.13) and DO (OR 1.06, 95% CI 1.03-1.08), respectively. 
Conclusion: Our study demonstrates a correlation between obesity and OAB/DO in female patients. 
However, other components of MetS do not appear to be associated with either OAB and DO. Weight 
reduction should be strongly recommended in women with OAB. 
Introduction 
Overactive bladder (OAB) is a highly prevalent symptom complex that is estimated to affect 12.8% of 
women and 10.8% of men [1].  It is associated with a significant impairment of  health-related quality 
of life and, subsequently, with a substantial economic burden [2]. The International Urogynaecological 
Association (IUGA) and International Continence Society (ICS) defined OAB as urinary urgency, usually 
accompanied by frequency and nocturia, with or without urgency urinary incontinence, in the absence 
of urinary tract infection or other obvious pathology [3]. OAB has usually been  linked to the 
urodynamic observation of detrusor overactivity (DO), which is the occurrence of involuntary detrusor 
contractions during filling cystometry. However, DO is demonstrated in only 44% of women and 69% 
of men with OAB [4]. The underlying pathophysiological mechanism of OAB and DO is poorly 
understood. It is thought that, not only the detrusor muscle, but also urothelium, peripheral afferent 
terminals and pelvic blood vessels may play a role . 
Since the last decade, authors have looked into a causal relationship between markers of the 
metabolic syndrome (MetS) and lower urinary tract symptoms (LUTS) [5]. MetS represents a cluster 
of cardiovascular disease (CVD) risk factors including obesity, dyslipidaemia, hypertension and glucose 
intolerance . Its rapidly increasing prevalence has recently been reported as 33% in the United States 
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[6]. However, comparisons between populations are challenging as numerous attempts have been 
made to define MetS and a conclusive agreement has not yet been received [7].  
Several urological conditions, such as benign prostatic hyperplasia, nephrolithiasis, erectile 
dysfunction and OAB have been associated with different aspects of the MetS [8]. A number of 
mechanisms may be involved, mainly secondary to insulin-resistance and the subsequent production 
of chronic pelvic ischemia . However, while there is increasing evidence of a link between components 
of the MetS and OAB in men, limited data are available with regard to women [9,10]. Moreover, 
although it has been acknowledged that patients with DO experience more severe OAB symptoms 
[11], urodynamic findings have not been considered in the existing literature. A more comprehensive 
assessment of  LUTS with urodynamics might give new insights. 
The aims of this study were to determine whether there is a link between different aspects of the 
MetS and OAB/DO in women with LUTS. 
Materials and methods 
We prospectively studied a cohort of consecutive women with LUTS attending a urodynamic clinic in 
a tertiary referral urogynaecology department between October 2012 and January 2015. Formal 
ethical approval was obtained by the local Research Ethics Committees (12/SC/0012). We included 
women complaining of any LUTS [storage, urinary incontinence (UI), sensory, voiding and post-
micturition symptoms]. Patients with at least one of the following characteristics were excluded: age 
< 18 years old, neurological condition affecting bladder function (such as dementia, stroke, multiple 
sclerosis, spinal cord injury and Parkinsons’s disease), urine dipstick positive for nitrites and inability 
to fill out a questionnaire in the English language.  
All women were asked to complete the validated King’s Health Questionnaire [12] and a 3-day 
frequency-volume chart, including the Patient’s Perception of Intensity of Urgency Scale (PPIUS) [13]. 
Antimuscarinic medications and mirabegron were stopped 7 days prior to attendance in the clinic, 
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where a detailed history was taken. Obesity, diabetes, hypertension and dyslipidaemia were 
considered as markers of MetS. Anthropometric measurements were calculated, including weight, 
height and body mass index (BMI) (weight [kg]/height [m]2). Normal weight, overweight or obesity 
were defined as BMI  25 or less, between 26 and 30,  or more than 30, respectively. Information 
regarding diabetes, hypertension and dyslipidaemia were collected from hospital records and patients 
were considered affected if already on relevant medical treatment.   
Patients were asked to attend with a reasonably full bladder in order to obtain a uroflow study. A 
dipstick test to exclude urinary infection was performed. Examination findings were described using 
the pelvic organ prolapse quantification (POPQ) system during maximal Valsalva [14]. A Laborie 
Aquarius Triton machine was used to perform multichannel urodynamics by trained nurse specialists  
and  trainees in urogynaecology in keeping with Good Urodynamic Practice [15].  
Standard subtracted cystometry was performed with the patient in the supine position at a filling rate 
of 100 mL/min with physiological saline at room temperature. When DO did not occur, and following 
removal of the filling catheter, patients were instructed to perform provocative tasks (moving to the 
standing position, coughing, listening to running water and washing hands) and, finally, they were 
asked to void to completion.  
Data were collected using a standardised proforma. Descriptive statistics were calculated for 
demographic information and clinical features. Several factors, including age, parity, menopausal 
status and markers for MetS (BMI, hypertension, diabetes mellitus and dyslipidaemia)  were  
considered. These have been combined with both urinary symptoms and urodynamic diagnosis. 
Bivariate and multivariate logistic regression analyses were performed with associations presented as 
odds ratios (ORs) with 95% confidence intervals (95% CIs). When statistical significance, defined with 
a p-value of <0.05, was achieved in univariate analysis, covariates were entered into the multivariate 
model. SPSS (V22, Chicago, IL, USA) was used for statistical analysis. 
Results 
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Eight hundred and forty women were enrolled in the study. The mean age was 50.6 years (SD: 14.4) 
and the median parity was 2 (range 0-7). Four hundred and eighteen (49.8%) were postmenopausal. 
Three hundred and eight (36.6%) had normal weight, 260 (31%) were overweight and 272 (32.4%) 
obese. Table 1 shows the characteristics of the study group. We identified 168 women (20%) with 
hypertension, 64 (7.6%) with diabetes mellitus, and 98 (11.7%) with dyslipidaemia. Seven hundred 
and four (83.8%) women were diagnosed symptomatically with OAB, in particular 574 (68.3%) with 
“wet” OAB and 130 (15.4%) with “dry” OAB. Three hundred and five (36.3%) were diagnosed 
urodynamically with DO. Out of the 704 women with OAB, 282 (40%) were found to have DO. On the 
other hand, out of 305 patients with DO, 282 (92.4%) were reporting OAB symptoms. Figure 1 displays 
the study’s flowchart.  
Table 2 and Table 3 report associations with outcomes OAB and DO, respectively. With regard to OAB, 
age (p=0.012) and BMI (p<0.001) were found to be significant at univariate analyses, but only BMI (OR 
1.09, 95% CI 1.05-1.13, p<0.001) maintained significance at multivariate analysis. When the outcome 
DO was considered, univariate analyses revealed significance for multiple factors, such as parity 
(p<0.001), BMI (p<0.001), hypertension (p=0.003) and diabetes mellitus (p=0.004). However, BMI (OR 
1.06, 95% CI 1.03-1.08, p<0.001) was still the only independent predictor at multivariate analysis. No 
associations were found for menopausal status and dyslipidaemia with either outcome.  
Discussion 
In this study we evaluated associations between different aspects of the MetS with both  OAB and DO 
in a cohort of women with LUTS. Unlike dyslipidaemia, hypertension and diabetes, obesity was a 
statistically significant risk factor for OAB and DO. To our knowledge, this is the first study considering 
DO, an objective diagnosis, alongside the symptom-based diagnosis of OAB.  
Current evidence is conflicting but a link between MetS and OAB in female patients has been 
previously demonstrated [16-18]. Different definitions for MetS have been used, including the 
diagnostic criteria determined by the Ministry of Health, Labour and Welfare in Japan [16], the 
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National Cholesterol Education Program Adult Treatment Panel III criteria [17] and the International 
Diabetes Federation criteria [18]. Interestingly, international associations deem that MetS itself is still 
imprecisely defined [19] and, therefore, care should be taken before drawing definitive conclusions. 
Until much needed research is completed, clinicians should evaluate and treat all CVD risk factors, 
regardless the criteria for diagnosis of the MetS are met or not. Hence we focused on established 
aspects of MetS separately.  
We found that obesity was the only independent risk factor for OAB (OR 1.09, 95% CI 1.05-1.13) and 
DO (OR 1.06, 95% CI 1.03-1.08). This is consistent with previously published studies [20-22]. Teleman 
et al. [20] evaluated 2682 women based on symptoms reported in the Bristol Female Lower Urinary 
Tract Symptoms questionnaire  and BMI ≥ 30 (OR 1.5, 95% CI 1.1-2.1) resulted as an independent risk 
factor for OAB symptoms reported as “sometimes” or more often. 3962 females responded to a 
validated mailed survey [21] using the Epidemiology of Prolapse and Incontinence questionnaire. 
Women with BMI ≥ 30 were over twice as likely to experience OAB (OR 2.97, 95% CI 2.20-3.22). De 
Boer et al. [22] analysed 1397 women who filled out a validated Dutch translation of the Urinary 
Distress Inventory and, again, a BMI ≥ 30 resulted as an indipendent risk factor for OAB (OR 2.3, 95% 
CI 1.7-3.2). It is acknowledged that raised BMI can affect the detrusor muscle and chronically impair 
bladder function. However, these three studies show a stronger impact of BMI on OAB symptoms and 
the reason for this could lie in the analysed samples. In fact, while they evaluated low risk women 
from population registers, we considered patients attending a tertiary referral urogynaecology 
department. By definition, our sample is more likely to have complex medical and surgical histories, 
which might be able to affect the impact of BMI on OAB symptoms.  
The role of the BMI is also supported by trials evaluating women’s LUTS following bariatric surgery 
[23,24]. Of note, while most of the studies considered the effects on urinary incontinence, Palleschi 
et al. [24] assessed OAB severity in 120 morbidly obese patients following sleeve gastrectomy. At 6-
month postoperatively, a significant reduction in the degree of bothersome OAB was noted. 
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Interestingly, Luke et al. [23] found that improvement in LUTS occurred early after bariatric 
procedures, suggesting an underlying mechanism other than just the weight loss. This could be 
represented by the insulin resistance, that can resolve early following bariatric surgery. 
In our study, diabetes was not associated with OAB symptoms. When DO was considered as an 
outcome, diabetes showed a trend close to significance (OR 1.61, 95% CI 0.93-2.76, p=0.08). This 
conflicts with published literature. In a population-based study, Lawrence et al. [21] found that women 
with diabetes were 90% more likely to have OAB than women without diabetes (OR 1.90, 95% CI 1.46-
2.49). In a large population-based study analysis including multiparous women of premenopausal age, 
a history of gestational diabetes was associated with double odds of OAB (OR 2.11, 95% CI 1.47-3.03) 
[25]. Interestingly, insulin resistance can adversely affect bladder nerves, smooth muscles and 
urothelium  leading to DO in patients with diabetic cystopathy [26]. The variable diabetes was the 
least represented in our study, as 64 (7.6%) patients were affected. Therefore, in a larger sample, 
diabetes could reach significance and become a risk factor/predictor for DO.  
We failed to demonstrate a link between the variables hypertension and dyslipidemia with either OAB 
and DO. This confirms the findings of Teleman et al. [20]. However, evidence in the literature is still 
limited. A population-based survey analysed 3599 women and, after adjustment for confounders, did 
not show a significant association between OAB and dyslipidaemia [27]. These variables were taken 
into account when a diagnosis of MetS was considered and a link with OAB was shown [16-18]. Further 
studies are required to shed light on these associations.   
There is growing interest in a causative relationship between markers of MetS and LUTS. A common 
aetiology could underlie both conditions, but consensus is still lacking. Our findings support a 
“mechanical” mechanism. In fact, there is a correlation between increased BMI and intra-abdominal 
pressure, which can chronically stress the pelvic floor. Recently, studies have focused on the role of 
chronic pelvic ischemia and subsequent reduced blood flow to the bladder as causative factor for LUTS 
[28]. Animal models have been used to study ischaemia induced bladder dysfunction. It  has been  
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argued that DO could derive from reactive oxygen species formed following ischaemia/reperfusion 
[29]. However, we cannot support this theory as there was no significant impact of dyslipidaemia, 
hypertension and diabetes with regard, not only to OAB, but also to DO.  
Among the limitations of our study, we recognise that MetS was not defined using agreed criteria and 
the period of time from initial diagnosis was not considered. We acknowledge this may influence OAB 
symptoms. In addition, we investigated the role of different aspects of the MetS in a population of 
women presenting with LUTS in our tertiary referral centre. As a consequence, despite the 
considerable size of the study population, conditions such as diabetes mellitus and dyslipidaemia were 
little represented and our study might be underpowered for drawing definite conclusions, in particular 
with regard to the MetS complex. However, post-hoc analysis using the formula by Peduzzi et al. [30] 
[N = 10 k / p, where k equals the number of covariates (independent variables) and p the smallest of 
the proportions of negative or positive cases in the population] suggested that we enrolled an 
adequate number of women. A minimum sample size of 432 ( 10 x 7 / 0.162 ) and 192 ( 10 x 7 / 0.363 
) was required for either outcomes OAB and DO, respectively. A waist circumference was not 
measured and diagnoses were based upon hospital records. Thus, cases of dyslipidaemia might have 
been underdiagnosed. Moreover, factors associated with urgency, such as smoking or alcohol 
consumption, have not been considered.  Whilst MetS components have an impact, the analysis of 
recognised confounding factors might provide clinicians with additional and more functional 
information. Furthermore, a history of stress UI was not included in our analysis. In fact, OAB 
symptoms might develop as a consequence of “defensive voiding”, leading women to increase the 
number of micturitions/day in order to reduce the amount of urine in the bladder and, thus, 
inconvenient episodes of UI.  
In conclusion, our present study on a link between aspects of MetS and OAB in female patients 
confirms a correlation between obesity and OAB. This is also supported by significantly increased odds 
of DO at urodynamics in raised BMI patients. However, other components of MetS do not appear to 
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be associated with either OAB and DO. Hence OAB cannot be considered an aspect of the MetS in 
female patients. We consider that a “mechanical” pathophysiological mechanism, mainly increased 
chronic intra-abdominal pressure, might explain our findings. Since obesity is a modifiable factor, 
weight reduction should be encouraged in women with LUTS. The possible benefits could also enhance 
the effectiveness of concomitant treatments, such as bladder retraining and medical therapy. Future 
analyses might explore the therapeutic value of combining these interventions in patients with OAB. 
Inclusion of women with all aspects of the MetS should be considered to achieve a more 
comprehensive understanding of a link between MetS and OAB. 
   
Table 1. Baseline characteristics of the study population  
Table 2. Outcome: OAB 
Table 3. Outcome: DO 
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Figr-1 
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Table 1. Baseline characteristics of the study population (n=840) 
Age, years,  mean (SD) 50.6 (14.4)  
Parity, median (range) 2 (0-7) 
BMI, kg/m2, n (%) 
  <25 
  25-29.9 
  ≥ 30 
 
308 (36.6) 
260 (31) 
272 (32.4) 
Menopausal, n(%) 418 (49.7) 
Previous surgical procedures, n (%) 
  Hysterectomy 
  Pelvic Floor Repair 
  Urinary Incontinence  
 
186 (22.1) 
89 (10.6) 
85 (10.1) 
King’s Health Questionnaire, median (range) 
  General Health Perception 
  Incontinence Impact 
  Role Limitations 
  Social Limitations 
  Physical Limitations 
  Personal Relationships 
  Emotions 
  Sleep/Energy 
  Severity/Coping Measures     
 
25 (0-100) 
66 (0-100) 
50 (0-100) 
50 (0-100) 
22 (0-100) 
33 (0-100) 
44 (0-100) 
50 (0-100) 
50 (0-100) 
Bladder diary, median (range) 
  Daily urgency episodes   
  Daytime voids 
  Nighttime voids 
  Maximum functional capacity, mls 
 
3 (0-14) 
8 (4-24) 
1 (0-7) 
400 (90-1300) 
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Table 2 
(Outcome: OAB) 
 
 
Univariate Analyses Multivariate Analysis 
OR (95% CI) p-value OR (95% CI) p-value 
 
Age 
 
1.02 (1.00-1.02) 0.012* 1.00 (0.99-1.02) 0.24 
Parity 1.06 (0.96-1.18) 0.23   
Menopause 1.19 (0.89-1.59) 0.23   
 
BMI 
 
1.09 (1.05-1.13) <0.001* 1.09 (1.05-1.13) <0.001* 
Hypertension 1.41 (0.88-2.23) 0.15   
 
Diabetes mellitus 
 
1.74 (0.78-3.90) 0.17   
 
Dyslipidaemia 
 
1.19 (0.66-2.12) 0.56   
* statistical significance 
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Table 3 
(Outcome: DO) Univariate Analyses 
 
Multivariate Analysis 
 
OR (95% CI) p-value OR (95% CI) p-value 
 
Age 
 
1.01 (0.99-1.01) 0.23   
 
Parity 
 
1.16 (1.07-1.25) <0.001* 1.03 (0.93-1.15) 0.52 
 
Menopause 
 
0.93 (0.74-1.18) 0.54   
 
BMI 
 
1.06 (1.04-1.09) <0.001* 1.06 (1.03-1.08) <0.001* 
 
Hypertension 
 
1.68 (1.19-2.36) 0.003* 1.27 (0.88-1.84) 0.20 
 
Diabetes mellitus 
 
2.12 (1.27-3.54) 0.004* 1.61 (0.93-2.76) 0.08 
 
Dyslipidaemia 
 
1.43 (0.94-2.20) 0.097   
*statistical significance 
 
 
